Profund Advisors LLC lifted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 77.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 141,985 shares of the biotechnology company’s stock after buying an additional 61,966 shares during the period. Profund Advisors LLC’s holdings in BioCryst Pharmaceuticals were worth $1,107,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also made changes to their positions in the stock. Royal Bank of Canada boosted its stake in shares of BioCryst Pharmaceuticals by 2.4% in the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after buying an additional 1,458 shares during the period. Captrust Financial Advisors boosted its stake in shares of BioCryst Pharmaceuticals by 7.4% in the second quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock valued at $198,000 after buying an additional 1,527 shares during the period. Counterweight Ventures LLC boosted its stake in shares of BioCryst Pharmaceuticals by 2.1% in the fourth quarter. Counterweight Ventures LLC now owns 95,384 shares of the biotechnology company’s stock valued at $744,000 after buying an additional 2,000 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 2,115 shares during the period. Finally, Creative Planning lifted its stake in BioCryst Pharmaceuticals by 2.6% during the third quarter. Creative Planning now owns 88,477 shares of the biotechnology company’s stock worth $672,000 after purchasing an additional 2,280 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.
Insider Activity at BioCryst Pharmaceuticals
In other news, insider Alane P. Barnes sold 150,000 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $9.15, for a total value of $1,372,500.00. Following the completion of the transaction, the insider directly owned 400,703 shares in the company, valued at approximately $3,666,432.45. This represents a 27.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.10% of the company’s stock.
Analyst Ratings Changes
View Our Latest Report on BioCryst Pharmaceuticals
BioCryst Pharmaceuticals Price Performance
NASDAQ BCRX opened at $8.37 on Friday. The business has a fifty day moving average price of $9.17 and a two-hundred day moving average price of $7.95. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.31. The stock has a market capitalization of $2.13 billion, a PE ratio of -4.70 and a beta of 0.57.
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The firm had revenue of $156.41 million during the quarter, compared to the consensus estimate of $151.12 million. During the same quarter in the previous year, the company posted $0.20 earnings per share. The firm’s revenue was up 7.5% on a year-over-year basis. As a group, sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.66 earnings per share for the current year.
BioCryst Pharmaceuticals Profile
BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.
The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.
Featured Stories
- Five stocks we like better than BioCryst Pharmaceuticals
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report).
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
